Preclinical studies have demonstrated that GPRC5D CAR‐T cells can effectively eliminate myeloma cells, including those resistant to BCMA‐targeted therapies, in xenografted mouse models. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.